angiotensin renin system blockade

systematic review meta-analysis network meta-analysis

Select diabetes type 2 All type of patient       angiotensin receptor blockerangiotensin-converting enzyme inhibitors captoprillisinoprilirbesartanlosartanolmesartan vs placebo or controlvs beta-blockersvs calcium-channel blockersvs diuretic and/or beta-blockervs diuretics      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (12)cardiovascular events (8)myocardial infarction (fatal and non fatal) (7)stroke (fatal and non fatal) (7)microvascular events (7)Cardiovascular death (5)Non fatal stroke (2)Non fatal MI (2)macrovascular events (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	cardiovascular events
diabetes type 2
captopril
UKPDS 38, 1998	captopril or atenolol	control			Exploratory	suggesting
UKPDS 39, 1998	captopril	atenolol			Exploratory	negative
CAPP (diabetic subgroup), 1999	captopril	diuretic and/or beta-blockers			Exploratory	suggesting
irbesartan
IPDM (150mg), 2001	irbesartan	placebo			Low risk of bias	suggesting
IDNT (irbesartan vs pbo), 2001	irbesartan	placebo			Low risk of bias	suggesting
IDNT (irbesartan vs amlodipine), 2001	irbesartan	amlodipine			Low risk of bias	suggesting
lisinopril
ALLHAT (lisi vs chlor, diabetic subgroup), 2002	lisinopril	chlorthalidone			Low risk of bias	negative
losartan
RENAAL, 2001	losartan	placebo			Low risk of bias	suggesting
olmesartan
ROADMAP, 2010        NCT	olmesartan	placebo			Low risk of bias	suggesting
ORIENT    NCT	olmesartan	placebo			Low risk of bias	negative